GLP-1 Analogues Market by Product (Ozempic, Rybelsus, Saxenda, Wegovy, Mounjaro, Zepbound, Victoza, Trulicity), Format (Single dose, Multi-dose, Tablets), ROA (Subcutaneous, Oral), Indication (Diabetes, Obesity) - Global Forecast to 2032
The GLP-1 Analogues market is expected to reach USD 471.1 billion by 2032 from USD 47.4 billion in 2024, at a CAGR of 33.2% during the forecast period. The key factors driving the growth of the GLP-1 Analogues market include the growing popularity of the GLP-1 drug class for the treatment of chronic obesity and weight management and high efficacy of GLP-1 analogues for treating type 2 diabetes. Additionally, innovation focusing on the development of convenient forms of GLP-1 drugs, such as oral dosage forms and single dose autoinjectors, are expected to drive growth of GLP-1 analogues market.
The GLP-1 Analogues market has been segmented based on products, format, route of administration, indication, and end-user.
“By product, Zepbound (tirzepatide) drug is forecasted to grow at the fastest rate in the GLP-1 Analogues market”
Based on product, the GLP-1 Analogues market is categorized into Ozempic (semaglutide), Trulicity (dulaglutide), Mounjaro (tirzepatide), Wegovy (semaglutide), Rybelsus (semaglutide), Saxenda (liraglutide [rDNA origin] injection), Victoza (liraglutide), Xultophy 100/3.6 (insulin degludec and liraglutide injection), Soliqua 100/33 (insulin glargine and lixisenatide injection), Zepbound (tirzepatide), Bydureon (exenatide extended-release), and other products. Zepbound is expected to experience fastest growth during the forecast period owing to factors such as approval of the drug for the treatment of obesity, exponential revenue growth observed since launch of the drug in 2023, and growing adoption of tirzepatide for obesity and weight management.
“By product format, the single dose format segment accounted for the largest share in the GLP-1 Analogues market”
Based on product format, the GLP-1 Analogues market is segmented into single-dose, multi-dose, and tablets. In 2023, the single-dose format segment accounted for the largest share of the GLP-1 Analogues market. Growth in this market segment can be attributed to the ease of administration and lower injection frequencies offered by single-dose format, together with the growing availability of single-dose auto-injectors.
“North America: accounted for the largest share of the GLP-1 Analogues market”
North America accounted for the largest share of the GLP-1 Analogues market. The large share of the North American region can be attributed to growing investments and funding in biomedical research by government bodies and pharmaceutical & biotechnology companies. Early adoption of emerging technologies and alternative therapies, supported by the availability of the majority of GLP-1 products in the region, further supports market growth. Also, a strong established presence of several market players in the region is another key factor supporting market growth. These key companies include Eli Lilly and Company (US), Novo Nordisk A/S (Denmark).
“Europe: The second-largest region in the GLP-1 Analogues market.”
The Europe GLP-1 Analogues market is the second largest market for GLP-1 Analogue drugs. This is attributed to the presence of a large number of academic and research institutes in this region, growing investments by market players and government institutes, and an increasing focus on research and development activities.
The primary interviews conducted for this report can be categorized as follows:
Novo Nordisk A/S (Denmark), Eli Lilly and Company (US), Sanofi (France), AstraZeneca (UK), Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (China), Boehringer Ingelheim International GmbH (Germany), Innovent (China), Paige Biopharmaceutical (Suzhou) Co., Ltd. (China), Sciwind Biosciences Co., Ltd. (China), Zealand Pharma A/S (Denmark), Beijing Dongfang Baitai Biotechnology Co., Ltd (China), and Jiangsu Hengrui Pharmaceuticals Co., Ltd. (China)
Research Coverage:
This report provides a detailed picture of the GLP-1 Analogues market. It aims to estimate the size and future growth potential of the market across different segments, such as the product, product format, route of administration, indication, end user, and region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders and new entrants by providing them with the closest approximations of the revenue numbers for the GLP-1 Analogues market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their businesses and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.
The report provides insights on the following pointers”
The GLP-1 Analogues market has been segmented based on products, format, route of administration, indication, and end-user.
“By product, Zepbound (tirzepatide) drug is forecasted to grow at the fastest rate in the GLP-1 Analogues market”
Based on product, the GLP-1 Analogues market is categorized into Ozempic (semaglutide), Trulicity (dulaglutide), Mounjaro (tirzepatide), Wegovy (semaglutide), Rybelsus (semaglutide), Saxenda (liraglutide [rDNA origin] injection), Victoza (liraglutide), Xultophy 100/3.6 (insulin degludec and liraglutide injection), Soliqua 100/33 (insulin glargine and lixisenatide injection), Zepbound (tirzepatide), Bydureon (exenatide extended-release), and other products. Zepbound is expected to experience fastest growth during the forecast period owing to factors such as approval of the drug for the treatment of obesity, exponential revenue growth observed since launch of the drug in 2023, and growing adoption of tirzepatide for obesity and weight management.
“By product format, the single dose format segment accounted for the largest share in the GLP-1 Analogues market”
Based on product format, the GLP-1 Analogues market is segmented into single-dose, multi-dose, and tablets. In 2023, the single-dose format segment accounted for the largest share of the GLP-1 Analogues market. Growth in this market segment can be attributed to the ease of administration and lower injection frequencies offered by single-dose format, together with the growing availability of single-dose auto-injectors.
“North America: accounted for the largest share of the GLP-1 Analogues market”
North America accounted for the largest share of the GLP-1 Analogues market. The large share of the North American region can be attributed to growing investments and funding in biomedical research by government bodies and pharmaceutical & biotechnology companies. Early adoption of emerging technologies and alternative therapies, supported by the availability of the majority of GLP-1 products in the region, further supports market growth. Also, a strong established presence of several market players in the region is another key factor supporting market growth. These key companies include Eli Lilly and Company (US), Novo Nordisk A/S (Denmark).
“Europe: The second-largest region in the GLP-1 Analogues market.”
The Europe GLP-1 Analogues market is the second largest market for GLP-1 Analogue drugs. This is attributed to the presence of a large number of academic and research institutes in this region, growing investments by market players and government institutes, and an increasing focus on research and development activities.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 70% and Demand Side 30%
- By Designation: Managers - 45%, Directors- 30%, and Executives - 25%
- By Country: North America- 40%, Europe- 30%, Asia Pacific- 20%, Latin America- 5%, and Middle East and Africa- 5%
Novo Nordisk A/S (Denmark), Eli Lilly and Company (US), Sanofi (France), AstraZeneca (UK), Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (China), Boehringer Ingelheim International GmbH (Germany), Innovent (China), Paige Biopharmaceutical (Suzhou) Co., Ltd. (China), Sciwind Biosciences Co., Ltd. (China), Zealand Pharma A/S (Denmark), Beijing Dongfang Baitai Biotechnology Co., Ltd (China), and Jiangsu Hengrui Pharmaceuticals Co., Ltd. (China)
Research Coverage:
This report provides a detailed picture of the GLP-1 Analogues market. It aims to estimate the size and future growth potential of the market across different segments, such as the product, product format, route of administration, indication, end user, and region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders and new entrants by providing them with the closest approximations of the revenue numbers for the GLP-1 Analogues market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their businesses and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.
The report provides insights on the following pointers”
- Analysis of key drivers (Strong R&D pipeline, Improved relative efficacy of GLP-1 drugs), opportunities (Integration of GLP-1 drugs into telehealth and digital weight management programs), restraints (High barriers for new entrants due to duopoly), and challenges (Off-label use of GLP-1 drugs, High non-adherence to therapy after 12-24 months) influencing the growth of the GLP-1 Analogues market.
- Product Development/ Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the GLP-1 Analogues market.
- Market Development: Comprehensive information about lucrative markets- the report analyses the GLP-1 Analogues market across varied regions.
- Market Diversification: Exhaustive information about new drugs, untapped geographies, recent developments, and investments in the GLP-1 Analogues market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the GLP-1 analogues market.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 REGIONS COVERED
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET SIZE ESTIMATION
2.2.1 MARKET SIZE ASSESSMENT
2.3 MARKET GROWTH FORECAST
2.4 MARKET BREAKDOWN & DATA TRIANGULATION
2.5 STUDY ASSUMPTIONS
2.6 LIMITATIONS
2.7 RISK ANALYSIS
2.8 RECESSION IMPACT ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 GLP-1 ANALOGUES MARKET OVERVIEW
4.2 NORTH AMERICA: GLP-1 ANALOGUES MARKET SHARE, BY INDICATION AND COUNTRY (2023)
4.3 GLP-1 ANALOGUES MARKET SHARE, BY PRODUCT, 2024 VS. 2032
4.4 GLP-1 ANALOGUES MARKET SHARE, BY INDICATION, 2023
4.5 GLP-1 ANALOGUES MARKET SHARE, BY END USER, 2024 VS. 2032
4.6 GLP-1 ANALOGUES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Strong R&D pipeline
5.2.1.2 Improved relative efficacy of GLP-1 drugs
5.2.1.3 High demand, expanding insurance coverage, growing sales, increasing awareness, and positive outcomes
5.2.2 RESTRAINTS
5.2.2.1 High barriers for new entrants due to duopoly
5.2.3 OPPORTUNITIES
5.2.3.1 Extended therapeutic uses
5.2.3.2 Integration of GLP-1 drugs into telehealth and digital weight management programs
5.2.4 CHALLENGES
5.2.4.1 Off-label use of GLP-1 drugs
5.2.4.2 High non-adherence to therapy after 12–24 months
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE TREND OF GLP-1 ANALOGUES
5.4.2 AVERAGE SELLING PRICES OF TOP GLP-1 ANALOGUES, BY COUNTRY/REGION
5.5 TECHNOLOGY ANALYSIS
5.5.1 KEY TECHNOLOGIES
5.5.1.1 Chemical Synthesis
5.5.1.2 Recombinant DNA Technology
5.5.2 ADJACENT TECHNOLOGIES
5.5.2.1 Hydrogel Depot Technology
5.5.2.2 Technologies for oral delivery of GLP-1 analogues
5.6 PIPELINE ANALYSIS
5.7 TRADE DATA
5.8 PATENT ANALYSIS
5.8.1 METHODOLOGY
5.8.2 INNOVATION AND PATENT APPLICATIONS
5.8.3 TOP APPLICANTS
5.9 VALUE CHAIN ANALYSIS
5.1 SUPPLY CHAIN ANALYSIS
5.11 ECOSYSTEM ANALYSIS
5.11.1 GLP-1 ANALOGUES MARKET: ROLE OF RAW MATERIAL VENDORS
5.11.2 GLP-1 ANALOGUES MARKET: ROLE OF PRODUCT PROVIDERS AND PHASE 3 PIPELINE PRODUCT COMPANIES
5.11.3 GLP-1 ANALOGUES MARKET: ROLE OF END USERS
5.11.4 GLP-1 ANALOGUES MARKET: ROLE OF REGULATORY AUTHORITIES
5.12 PORTER’S FIVE FORCES ANALYSIS
5.12.1 THREAT OF NEW ENTRANTS
5.12.2 THREAT OF SUBSTITUTES
5.12.3 BARGAINING POWER OF SUPPLIERS
5.12.4 BARGAINING POWER OF BUYERS
5.12.5 INTENSITY OF COMPETITIVE RIVALRY
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.13.2 BUYING CRITERIA FOR GLP-1 ANALOGUES
5.14 REGULATORY LANDSCAPE
5.14.1 REGULATORY SCENARIO
5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.14.2.1 North America
5.14.2.2 Europe
5.14.2.3 Asia Pacific
5.14.2.4 Rest of the World
5.15 KEY CONFERENCES & EVENTS, 2024–2025
5.16 CASE STUDIES
5.16.1 STUDY OF TIRZEPATIDE AS A CASE IN GLP-1 DRUGS MARKET
5.16.2 OZEMPIC OFF-LABEL USE
5.17 INVESTMENT AND FUNDING SCENARIO
6 GLP-1 ANALOGUES MARKET, BY PRODUCT
6.1 INTRODUCTIONS
6.2 OZEMPIC
6.2.1 RISING ADOPTION TO SUPPORT MARKET GROWTH
6.3 TRULICITY
6.3.1 COMPETITOR REVENUE GROWTH TO AFFECT GROWTH
6.4 MOUNJARO
6.4.1 EXPONENTIAL GROWTH ANTICIPATED DUE TO HIGH ADOPTION IN NORTH AMERICA
6.5 WEGOVY
6.5.1 INCREASING USE FOR WEIGHT MANAGEMENT TO SUPPORT GROWTH
6.6 RYBELSUS
6.6.1 CONVENIENCE OF ORAL ADMINISTRATION TO DRIVE MARKET
6.7 SAXENDA
6.7.1 DEVELOPMENT OF GENERIC VERSIONS TO SLOW GROWTH
6.8 VICTOZA
6.8.1 ADOPTION OF ORAL GLP-1S TO RESTRAIN MARKET GROWTH
6.9 XULTOPHY
6.9.1 REGULATORY APPROVALS TO SUPPORT MARKET GROWTH
6.1 SOLIQUA
6.10.1 COMPETITOR GLP-1 PRODUCTS THREAT TO GROWTH
6.11 ZEPBOUND
6.11.1 STRONG REVENUE GROWTH TO ENSURE CONTINUED PRESENCE
6.12 BYDUREON
6.12.1 COMPETITOR PRODUCTS TO AFFECT MARKET GROWTH
6.13 OTHER PRODUCTS
7 GLP-1 ANALOGUES MARKET, BY FORMAT
7.1 INTRODUCTIONS
7.2 SINGLE DOSE
7.2.1 HIGH ADOPTION DUE TO EASE OF ADMINISTRATION TO SUPPORT GROWTH
7.3 MULTI-DOSE
7.3.1 LOW COST TO ATTRACT LARGER ADOPTION
7.4 TABLETS
7.4.1 DEVELOPMENT OF HIGH-POTENCY GLP-1S TO SUPPORT MARKET GROWTH
8 GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION
8.1 INTRODUCTION
8.2 SUBCUTANEOUS ADMINISTRATION
8.2.1 PEN INJECTORS
8.2.1.1 Ease of monitoring to support adoption
8.2.2 AUTOINJECTORS
8.2.2.1 Advantages offered over pen injectors to support adoption
8.3 ORAL ADMINISTRATION
8.3.1 ELIMINATION OF NEEDLE PHOBIA AND EASE OF USE TO DRIVE COMPLIANCE
9 GLP-1 ANALOGUES MARKET, BY INDICATION
9.1 INTRODUCTION
9.2 DIABETES
9.2.1 HIGH EFFICACY TO SUPPORT MARKET GROWTH
9.3 OBESITY
9.3.1 INCREASING DEMAND AND PIPELINE FOCUS ON ANTI-OBESITY GLP-1S TO DRIVE MARKET
9.4 OTHER INDICATIONS
10 GLP-1 ANALOGUES MARKET, BY END USER
10.1 INTRODUCTIONS
10.2 HOME CARE SETTINGS
10.2.1 RISING NUMBER OF TELEHEALTH COMPANIES AND CONVENIENCE OF HOME CARE TO SUPPORT MARKET GROWTH
10.3 LONG-TERM CARE FACILITIES
10.3.1 GROWING GERIATRIC POPULATION AND RISING CHRONIC DISEASE INCIDENCE TO DRIVE MARKET
10.4 HOSPITALS & SPECIALTY CLINICS
10.4.1 ADOPTION OF GLP-1 FOR VARIED INDICATIONS TO SUPPORT MARKET GROWTH
11 GLP-1 ANALOGUES MARKET, BY REGION
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 NORTH AMERICA: RECESSION IMPACT
11.2.2 US
11.2.2.1 Strategic developments by major players and R&D activities to drive market
11.2.3 CANADA
11.2.3.1 Strong research infrastructure and availability of funding to support market growth
11.3 EUROPE
11.3.1 EUROPE: RECESSION IMPACT
11.3.2 GERMANY
11.3.2.1 Improving accessibility to support market growth in Germany
11.3.3 UK
11.3.3.1 Increasing research to evaluate efficacy and potential of GLP-1 analogues to support market growth
11.3.4 FRANCE
11.3.4.1 Growing awareness to propel market growth
11.3.5 ITALY
11.3.5.1 Presence of major pharmaceutical and biotechnology companies to drive market
11.3.6 SPAIN
11.3.6.1 Favorable initiatives for research to drive market
11.3.7 NETHERLANDS
11.3.7.1 Growing awareness and strong focus on pharmaceutical R&D to support market growth
11.3.8 REST OF EUROPE
11.4 ASIA PACIFIC
11.4.1 ASIA PACIFIC: RECESSION IMPACT
11.4.2 CHINA
11.4.2.1 Expansion of major biotechnology and pharmaceutical companies in China to drive market
11.4.3 JAPAN
11.4.3.1 Growing availability of prominent GLP-1 drugs to drive market
11.4.4 INDIA
11.4.4.1 Strong initiatives to develop cost-effective and patient-friendly medications to aid market growth
11.4.5 AUSTRALIA
11.4.5.1 Access to GLP-1 drugs and government support to drive market
11.4.6 SOUTH KOREA
11.4.6.1 Collaborations in obesity drugs to propel market growth
11.4.7 REST OF ASIA PACIFIC
11.5 LATIN AMERICA
11.5.1 LATIN AMERICA: RECESSION IMPACT
11.5.2 BRAZIL
11.5.2.1 Brazil to hold largest market share in Latin America
11.5.3 MEXICO
11.5.3.1 Growing diabetes and obesity cases to support market growth
11.5.4 REST OF LATIN AMERICA
11.6 MIDDLE EAST
11.6.1 MIDDLE EAST: RECESSION IMPACT
11.6.2 GCC COUNTRIES
11.6.2.1 Saudi Arabia
11.6.2.1.1 Growing availability of GLP-1 drugs to support market growth
11.6.2.2 UAE
11.6.2.2.1 Growing regulatory approvals for GLP-1 drugs to support market growth
11.6.2.3 Rest of GCC countries
11.6.3 REST OF MIDDLE EAST
11.7 AFRICA
11.7.1 GROWING HEALTHCARE AND LIFE SCIENCE INDUSTRY TO SUPPORT GROWTH
11.7.2 AFRICA: RECESSION IMPACT
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 KEY PLAYER STRATEGY/RIGHT TO WIN
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN GLP-1 ANALOGUES MARKET
12.3 REVENUE ANALYSIS
12.4 MARKET SHARE ANALYSIS
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
12.6 COMPANY EVALUATION MATRIX: PLAYERS WITH PRODUCTS IN PIPELINE, 2023
12.6.1 STARS
12.6.2 EMERGING LEADERS
12.6.3 PERVASIVE PLAYERS
12.6.4 PARTICIPANTS
12.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
12.6.5.1 Company Footprint
12.6.5.2 Format footprint
12.6.5.3 Route of administration footprint
12.6.5.4 Indication footprint
12.6.5.5 Region footprint
12.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
12.7.1 PROGRESSIVE COMPANIES
12.7.2 RESPONSIVE COMPANIES
12.7.3 DYNAMIC COMPANIES
12.7.4 STARTING BLOCKS
12.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
12.8 VALUATION & FINANCIAL METRICS
12.8.1 FINANCIAL METRICS
12.8.2 COMPANY VALUATION
12.9 BRAND/PRODUCT COMPARISON
12.1 COMPETITIVE SCENARIO
12.10.1 PRODUCT APPROVALS
12.10.2 DEALS
12.10.3 EXPANSIONS
12.10.4 OTHER DEVELOPMENTS
13 COMPANY PROFILES
13.1 INTRODUCTION
13.2 KEY PLAYERS
13.2.1 NOVO NORDISK A/S
13.2.1.1 Business overview
13.2.1.2 Products offered
13.2.1.3 Recent developments
13.2.1.3.1 Product approvals
13.2.1.3.2 Expansions
13.2.1.3.3 Other developments
13.2.1.4 MnM view
13.2.1.4.1 Right to win
13.2.1.4.2 Strategic choices
13.2.1.4.3 Weaknesses & competitive threats
13.2.2 ELI LILLY AND COMPANY
13.2.2.1 Business overview
13.2.2.2 Products offered
13.2.2.3 Recent developments
13.2.2.3.1 Product approvals
13.2.2.3.2 Deals
13.2.2.3.3 Expansions
13.2.2.4 MnM view
13.2.2.4.1 Right to win
13.2.2.4.2 Strategic choices
13.2.2.4.3 Weaknesses & competitive threats
13.2.3 SANOFI
13.2.3.1 Business overview
13.2.3.2 Products offered
13.2.3.3 MnM view
13.2.3.3.1 Key strengths
13.2.3.3.2 Strategic choices
13.2.3.3.3 Weaknesses & competitive threats
13.2.4 ASTRAZENECA
13.2.4.1 Business overview
13.2.4.2 Products offered
13.2.4.3 Recent developments
13.2.4.3.1 Product approvals
13.2.4.4 MnM view
13.2.4.4.1 Right to win
13.2.4.4.2 Strategic choices
13.2.4.4.3 Weaknesses & competitive threats
13.2.5 JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.
13.2.5.1 Business overview
13.2.5.2 Products offered
13.2.6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
13.2.6.1 Business overview
13.2.6.2 Products in pipeline
13.2.6.3 Recent developments
13.2.6.3.1 Deals
13.2.6.3.2 Other developments
13.2.7 INNOVENT
13.2.7.1 Business overview
13.2.7.2 Products in pipeline
13.2.7.3 Recent developments
13.2.7.3.1 Other developments
13.2.8 PAIGE BIOPHARMACEUTICAL (SUZHOU) CO., LTD.
13.2.8.1 Business overview
13.2.8.2 Products in pipeline
13.2.9 SCIWIND BIOSCIENCES CO., LTD.
13.2.9.1 Business overview
13.2.9.2 Products in pipeline
13.2.9.3 Recent developments
13.2.9.3.1 Deals
13.2.9.3.2 Other developments
13.2.10 ZEALAND PHARMA A/S
13.2.10.1 Business overview
13.2.10.2 Products in pipeline
13.2.10.3 Recent developments
13.2.10.3.1 Deals
13.2.10.3.2 Other developments
13.2.11 BEIJING DONGFANG BAITAI BIOTECHNOLOGY CO., LTD (EASTERN BIOTECH)
13.2.11.1 Business overview
13.2.11.2 Products in pipeline
13.3 OTHER PLAYERS
13.3.1 SUN PHARMACEUTICAL INDUSTRIES LTD.
13.3.2 VTV THERAPEUTICS
13.3.3 TERNS PHARMACEUTICALS, INC.
13.3.4 ALTIMMUNE
13.3.5 SCOHIA PHARMA, INC.
13.3.6 STRUCTURE THERAPEUTICS
13.3.7 NEUROBO PHARMACEUTICALS, INC.
13.3.8 I2O THERAPEUTICS, INC.
13.3.9 AMGEN INC.
13.3.10 PFIZER INC.
13.3.11 MERCK & CO., INC.
13.3.12 HANMI PHARM CO., LTD.
13.3.13 VIKING THERAPEUTICS
13.3.14 JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.
14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 REGIONS COVERED
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET SIZE ESTIMATION
2.2.1 MARKET SIZE ASSESSMENT
2.3 MARKET GROWTH FORECAST
2.4 MARKET BREAKDOWN & DATA TRIANGULATION
2.5 STUDY ASSUMPTIONS
2.6 LIMITATIONS
2.7 RISK ANALYSIS
2.8 RECESSION IMPACT ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 GLP-1 ANALOGUES MARKET OVERVIEW
4.2 NORTH AMERICA: GLP-1 ANALOGUES MARKET SHARE, BY INDICATION AND COUNTRY (2023)
4.3 GLP-1 ANALOGUES MARKET SHARE, BY PRODUCT, 2024 VS. 2032
4.4 GLP-1 ANALOGUES MARKET SHARE, BY INDICATION, 2023
4.5 GLP-1 ANALOGUES MARKET SHARE, BY END USER, 2024 VS. 2032
4.6 GLP-1 ANALOGUES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Strong R&D pipeline
5.2.1.2 Improved relative efficacy of GLP-1 drugs
5.2.1.3 High demand, expanding insurance coverage, growing sales, increasing awareness, and positive outcomes
5.2.2 RESTRAINTS
5.2.2.1 High barriers for new entrants due to duopoly
5.2.3 OPPORTUNITIES
5.2.3.1 Extended therapeutic uses
5.2.3.2 Integration of GLP-1 drugs into telehealth and digital weight management programs
5.2.4 CHALLENGES
5.2.4.1 Off-label use of GLP-1 drugs
5.2.4.2 High non-adherence to therapy after 12–24 months
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE TREND OF GLP-1 ANALOGUES
5.4.2 AVERAGE SELLING PRICES OF TOP GLP-1 ANALOGUES, BY COUNTRY/REGION
5.5 TECHNOLOGY ANALYSIS
5.5.1 KEY TECHNOLOGIES
5.5.1.1 Chemical Synthesis
5.5.1.2 Recombinant DNA Technology
5.5.2 ADJACENT TECHNOLOGIES
5.5.2.1 Hydrogel Depot Technology
5.5.2.2 Technologies for oral delivery of GLP-1 analogues
5.6 PIPELINE ANALYSIS
5.7 TRADE DATA
5.8 PATENT ANALYSIS
5.8.1 METHODOLOGY
5.8.2 INNOVATION AND PATENT APPLICATIONS
5.8.3 TOP APPLICANTS
5.9 VALUE CHAIN ANALYSIS
5.1 SUPPLY CHAIN ANALYSIS
5.11 ECOSYSTEM ANALYSIS
5.11.1 GLP-1 ANALOGUES MARKET: ROLE OF RAW MATERIAL VENDORS
5.11.2 GLP-1 ANALOGUES MARKET: ROLE OF PRODUCT PROVIDERS AND PHASE 3 PIPELINE PRODUCT COMPANIES
5.11.3 GLP-1 ANALOGUES MARKET: ROLE OF END USERS
5.11.4 GLP-1 ANALOGUES MARKET: ROLE OF REGULATORY AUTHORITIES
5.12 PORTER’S FIVE FORCES ANALYSIS
5.12.1 THREAT OF NEW ENTRANTS
5.12.2 THREAT OF SUBSTITUTES
5.12.3 BARGAINING POWER OF SUPPLIERS
5.12.4 BARGAINING POWER OF BUYERS
5.12.5 INTENSITY OF COMPETITIVE RIVALRY
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.13.2 BUYING CRITERIA FOR GLP-1 ANALOGUES
5.14 REGULATORY LANDSCAPE
5.14.1 REGULATORY SCENARIO
5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.14.2.1 North America
5.14.2.2 Europe
5.14.2.3 Asia Pacific
5.14.2.4 Rest of the World
5.15 KEY CONFERENCES & EVENTS, 2024–2025
5.16 CASE STUDIES
5.16.1 STUDY OF TIRZEPATIDE AS A CASE IN GLP-1 DRUGS MARKET
5.16.2 OZEMPIC OFF-LABEL USE
5.17 INVESTMENT AND FUNDING SCENARIO
6 GLP-1 ANALOGUES MARKET, BY PRODUCT
6.1 INTRODUCTIONS
6.2 OZEMPIC
6.2.1 RISING ADOPTION TO SUPPORT MARKET GROWTH
6.3 TRULICITY
6.3.1 COMPETITOR REVENUE GROWTH TO AFFECT GROWTH
6.4 MOUNJARO
6.4.1 EXPONENTIAL GROWTH ANTICIPATED DUE TO HIGH ADOPTION IN NORTH AMERICA
6.5 WEGOVY
6.5.1 INCREASING USE FOR WEIGHT MANAGEMENT TO SUPPORT GROWTH
6.6 RYBELSUS
6.6.1 CONVENIENCE OF ORAL ADMINISTRATION TO DRIVE MARKET
6.7 SAXENDA
6.7.1 DEVELOPMENT OF GENERIC VERSIONS TO SLOW GROWTH
6.8 VICTOZA
6.8.1 ADOPTION OF ORAL GLP-1S TO RESTRAIN MARKET GROWTH
6.9 XULTOPHY
6.9.1 REGULATORY APPROVALS TO SUPPORT MARKET GROWTH
6.1 SOLIQUA
6.10.1 COMPETITOR GLP-1 PRODUCTS THREAT TO GROWTH
6.11 ZEPBOUND
6.11.1 STRONG REVENUE GROWTH TO ENSURE CONTINUED PRESENCE
6.12 BYDUREON
6.12.1 COMPETITOR PRODUCTS TO AFFECT MARKET GROWTH
6.13 OTHER PRODUCTS
7 GLP-1 ANALOGUES MARKET, BY FORMAT
7.1 INTRODUCTIONS
7.2 SINGLE DOSE
7.2.1 HIGH ADOPTION DUE TO EASE OF ADMINISTRATION TO SUPPORT GROWTH
7.3 MULTI-DOSE
7.3.1 LOW COST TO ATTRACT LARGER ADOPTION
7.4 TABLETS
7.4.1 DEVELOPMENT OF HIGH-POTENCY GLP-1S TO SUPPORT MARKET GROWTH
8 GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION
8.1 INTRODUCTION
8.2 SUBCUTANEOUS ADMINISTRATION
8.2.1 PEN INJECTORS
8.2.1.1 Ease of monitoring to support adoption
8.2.2 AUTOINJECTORS
8.2.2.1 Advantages offered over pen injectors to support adoption
8.3 ORAL ADMINISTRATION
8.3.1 ELIMINATION OF NEEDLE PHOBIA AND EASE OF USE TO DRIVE COMPLIANCE
9 GLP-1 ANALOGUES MARKET, BY INDICATION
9.1 INTRODUCTION
9.2 DIABETES
9.2.1 HIGH EFFICACY TO SUPPORT MARKET GROWTH
9.3 OBESITY
9.3.1 INCREASING DEMAND AND PIPELINE FOCUS ON ANTI-OBESITY GLP-1S TO DRIVE MARKET
9.4 OTHER INDICATIONS
10 GLP-1 ANALOGUES MARKET, BY END USER
10.1 INTRODUCTIONS
10.2 HOME CARE SETTINGS
10.2.1 RISING NUMBER OF TELEHEALTH COMPANIES AND CONVENIENCE OF HOME CARE TO SUPPORT MARKET GROWTH
10.3 LONG-TERM CARE FACILITIES
10.3.1 GROWING GERIATRIC POPULATION AND RISING CHRONIC DISEASE INCIDENCE TO DRIVE MARKET
10.4 HOSPITALS & SPECIALTY CLINICS
10.4.1 ADOPTION OF GLP-1 FOR VARIED INDICATIONS TO SUPPORT MARKET GROWTH
11 GLP-1 ANALOGUES MARKET, BY REGION
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 NORTH AMERICA: RECESSION IMPACT
11.2.2 US
11.2.2.1 Strategic developments by major players and R&D activities to drive market
11.2.3 CANADA
11.2.3.1 Strong research infrastructure and availability of funding to support market growth
11.3 EUROPE
11.3.1 EUROPE: RECESSION IMPACT
11.3.2 GERMANY
11.3.2.1 Improving accessibility to support market growth in Germany
11.3.3 UK
11.3.3.1 Increasing research to evaluate efficacy and potential of GLP-1 analogues to support market growth
11.3.4 FRANCE
11.3.4.1 Growing awareness to propel market growth
11.3.5 ITALY
11.3.5.1 Presence of major pharmaceutical and biotechnology companies to drive market
11.3.6 SPAIN
11.3.6.1 Favorable initiatives for research to drive market
11.3.7 NETHERLANDS
11.3.7.1 Growing awareness and strong focus on pharmaceutical R&D to support market growth
11.3.8 REST OF EUROPE
11.4 ASIA PACIFIC
11.4.1 ASIA PACIFIC: RECESSION IMPACT
11.4.2 CHINA
11.4.2.1 Expansion of major biotechnology and pharmaceutical companies in China to drive market
11.4.3 JAPAN
11.4.3.1 Growing availability of prominent GLP-1 drugs to drive market
11.4.4 INDIA
11.4.4.1 Strong initiatives to develop cost-effective and patient-friendly medications to aid market growth
11.4.5 AUSTRALIA
11.4.5.1 Access to GLP-1 drugs and government support to drive market
11.4.6 SOUTH KOREA
11.4.6.1 Collaborations in obesity drugs to propel market growth
11.4.7 REST OF ASIA PACIFIC
11.5 LATIN AMERICA
11.5.1 LATIN AMERICA: RECESSION IMPACT
11.5.2 BRAZIL
11.5.2.1 Brazil to hold largest market share in Latin America
11.5.3 MEXICO
11.5.3.1 Growing diabetes and obesity cases to support market growth
11.5.4 REST OF LATIN AMERICA
11.6 MIDDLE EAST
11.6.1 MIDDLE EAST: RECESSION IMPACT
11.6.2 GCC COUNTRIES
11.6.2.1 Saudi Arabia
11.6.2.1.1 Growing availability of GLP-1 drugs to support market growth
11.6.2.2 UAE
11.6.2.2.1 Growing regulatory approvals for GLP-1 drugs to support market growth
11.6.2.3 Rest of GCC countries
11.6.3 REST OF MIDDLE EAST
11.7 AFRICA
11.7.1 GROWING HEALTHCARE AND LIFE SCIENCE INDUSTRY TO SUPPORT GROWTH
11.7.2 AFRICA: RECESSION IMPACT
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 KEY PLAYER STRATEGY/RIGHT TO WIN
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN GLP-1 ANALOGUES MARKET
12.3 REVENUE ANALYSIS
12.4 MARKET SHARE ANALYSIS
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
12.6 COMPANY EVALUATION MATRIX: PLAYERS WITH PRODUCTS IN PIPELINE, 2023
12.6.1 STARS
12.6.2 EMERGING LEADERS
12.6.3 PERVASIVE PLAYERS
12.6.4 PARTICIPANTS
12.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
12.6.5.1 Company Footprint
12.6.5.2 Format footprint
12.6.5.3 Route of administration footprint
12.6.5.4 Indication footprint
12.6.5.5 Region footprint
12.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
12.7.1 PROGRESSIVE COMPANIES
12.7.2 RESPONSIVE COMPANIES
12.7.3 DYNAMIC COMPANIES
12.7.4 STARTING BLOCKS
12.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
12.8 VALUATION & FINANCIAL METRICS
12.8.1 FINANCIAL METRICS
12.8.2 COMPANY VALUATION
12.9 BRAND/PRODUCT COMPARISON
12.1 COMPETITIVE SCENARIO
12.10.1 PRODUCT APPROVALS
12.10.2 DEALS
12.10.3 EXPANSIONS
12.10.4 OTHER DEVELOPMENTS
13 COMPANY PROFILES
13.1 INTRODUCTION
13.2 KEY PLAYERS
13.2.1 NOVO NORDISK A/S
13.2.1.1 Business overview
13.2.1.2 Products offered
13.2.1.3 Recent developments
13.2.1.3.1 Product approvals
13.2.1.3.2 Expansions
13.2.1.3.3 Other developments
13.2.1.4 MnM view
13.2.1.4.1 Right to win
13.2.1.4.2 Strategic choices
13.2.1.4.3 Weaknesses & competitive threats
13.2.2 ELI LILLY AND COMPANY
13.2.2.1 Business overview
13.2.2.2 Products offered
13.2.2.3 Recent developments
13.2.2.3.1 Product approvals
13.2.2.3.2 Deals
13.2.2.3.3 Expansions
13.2.2.4 MnM view
13.2.2.4.1 Right to win
13.2.2.4.2 Strategic choices
13.2.2.4.3 Weaknesses & competitive threats
13.2.3 SANOFI
13.2.3.1 Business overview
13.2.3.2 Products offered
13.2.3.3 MnM view
13.2.3.3.1 Key strengths
13.2.3.3.2 Strategic choices
13.2.3.3.3 Weaknesses & competitive threats
13.2.4 ASTRAZENECA
13.2.4.1 Business overview
13.2.4.2 Products offered
13.2.4.3 Recent developments
13.2.4.3.1 Product approvals
13.2.4.4 MnM view
13.2.4.4.1 Right to win
13.2.4.4.2 Strategic choices
13.2.4.4.3 Weaknesses & competitive threats
13.2.5 JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.
13.2.5.1 Business overview
13.2.5.2 Products offered
13.2.6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
13.2.6.1 Business overview
13.2.6.2 Products in pipeline
13.2.6.3 Recent developments
13.2.6.3.1 Deals
13.2.6.3.2 Other developments
13.2.7 INNOVENT
13.2.7.1 Business overview
13.2.7.2 Products in pipeline
13.2.7.3 Recent developments
13.2.7.3.1 Other developments
13.2.8 PAIGE BIOPHARMACEUTICAL (SUZHOU) CO., LTD.
13.2.8.1 Business overview
13.2.8.2 Products in pipeline
13.2.9 SCIWIND BIOSCIENCES CO., LTD.
13.2.9.1 Business overview
13.2.9.2 Products in pipeline
13.2.9.3 Recent developments
13.2.9.3.1 Deals
13.2.9.3.2 Other developments
13.2.10 ZEALAND PHARMA A/S
13.2.10.1 Business overview
13.2.10.2 Products in pipeline
13.2.10.3 Recent developments
13.2.10.3.1 Deals
13.2.10.3.2 Other developments
13.2.11 BEIJING DONGFANG BAITAI BIOTECHNOLOGY CO., LTD (EASTERN BIOTECH)
13.2.11.1 Business overview
13.2.11.2 Products in pipeline
13.3 OTHER PLAYERS
13.3.1 SUN PHARMACEUTICAL INDUSTRIES LTD.
13.3.2 VTV THERAPEUTICS
13.3.3 TERNS PHARMACEUTICALS, INC.
13.3.4 ALTIMMUNE
13.3.5 SCOHIA PHARMA, INC.
13.3.6 STRUCTURE THERAPEUTICS
13.3.7 NEUROBO PHARMACEUTICALS, INC.
13.3.8 I2O THERAPEUTICS, INC.
13.3.9 AMGEN INC.
13.3.10 PFIZER INC.
13.3.11 MERCK & CO., INC.
13.3.12 HANMI PHARM CO., LTD.
13.3.13 VIKING THERAPEUTICS
13.3.14 JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.
14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
